Human Primary Alveolar Epithelial Cells from Cell Biologics are isolated from human lung tissue and grown in gelatin pre-coated tissue culture flask with Cell Biologics’ Complete Growth Medium. Cells at passage 3 are harvested from flasks and cryo-preserved in vials. Each vial contains 0.5x106 cells per ml and is delivered frozen. Human Primary Alveolar Epithelial Cells from Cell Biologics are characterized by immunofluorescent staining with E-cadherin (Catalog No. 610182 from BD) or ZO-1 (Catalog No. 617300; from Life Technologies) antibody. These Cells are negative for mycoplasma, bacteria, yeast, fungi, HIV-1, hepatitis B and hepatitis C and can be expanded for 3-5 passages at a split ratio of 1:2 under the cell culture conditions specified by Cell Biologics. Repeated freezing and thawing of cells are not recommended.
Cryopreserved cells are shipped with dry ice overnight. Upon arrival, transfer frozen cells to liquid nitrogen (-180°C) immediately until ready for use. Live cell shipment is also available on request. Primary cells can never be kept at -20 °C or -80 °C freezer.
Authorized Uses of Cell Biologics’ Products
Human Primary alveolar Epithelial Cells from Cell Biologics are distributed for research purposes only. Our products are not authorized for human use, for in vitro diagnostic or therapeutic procedures. Transfer or resale of any Cell Biologics’ cells or products from the purchaser to other markets, organizations or individuals is prohibited by Cell Biologics without the company’s written consent. Cell Biologics’ Terms and Conditions must be accepted before submitting an order.
Investigators should handle the cells received from Cell Biologics with caution and treat all primary cells as potential pathogens, since no test procedure can completely guarantee the absence of infectious agents. The entire text of discussing Biosafety in Microbiological and Biomedical Laboratories, 5th ed. is available online at http://www.cdc.gov/biosafety/publications/bmbl5/index.htm.
Nat Commun. 2023; 14: 6506.
Cancer Immunol Res. 2023 Jun 2; 11(6): 792–809.